Sourasky Medical Center (Ichilov)
Bookimed non aggiunge costi extra ai prezzi dei trattamenti di Anemia Emolitica. Le tariffe provengono dai listini ufficiali delle cliniche. Pagherai direttamente in clinica al tuo arrivo nel paese.
Bookimed si impegna per la tua sicurezza. Lavoriamo solo con strutture che mantengono elevati standard internazionali nei trattamenti di Anemia Emolitica e hanno le licenze necessarie per servire pazienti internazionali in tutto il mondo.
Bookimed offre assistenza esperta gratuita. Un coordinatore medico personale ti supporta prima, durante e dopo il trattamento, risolvendo qualsiasi problema. Non sarai mai solo nel tuo percorso di trattamento per Anemia Emolitica.
Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.
He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.
He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.
His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.
Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.
She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.
She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.
She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.
Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.
He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.
He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.
Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.
He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.
He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).
Tel Aviv Sourasky Medical Center and Sheba Medical Center are top-equipped Israeli hospitals for treating hemolytic anemia. These JCI-accredited tertiary centers provide specialized hematology units. They offer advanced immune-suppressing therapies and plasmapheresis. Both facilities maintain robust blood banks to manage severe crises safely.
Bookimed Expert Insight: Israeli hematology departments offer high-level expertise, but patient volume varies. Sourasky Medical Center treats over 1,800,000 patients annually across its departments. This high volume often results in more streamlined protocols for rare autoimmune cases. When choosing a specialist, look for leaders like Prof. Avichai Shimoni. His diverse background in pediatrics and adult hematology is vital for transition care.
Patient Consensus: Patients note it is important to find centers with active immunotherapy protocols. Many emphasize choosing doctors experienced with rituximab rather than rushing into a splenectomy.
Israeli hematologists identify hemolytic anemia types using a structured combination of laboratorial, morphological, and molecular techniques. Specialists employ direct antiglobulin testing (DAT) and flow cytometry to differentiate immune-mediated causes. Advanced centers use hemoglobin electrophoresis and next-generation sequencing for definitive hereditary diagnosis within JCI-accredited facilities.
Bookimed Expert Insight: Israeli hematology centers often use flow cytometry and PET/CT imaging as integrated prognostic tools for complex blood disorders. For example, Dr. Abraham Avigdor at Sheba Medical Center uses PET/CT to monitor treatment response. This allows doctors to adjust therapies faster than standard blood work alone might suggest. Choosing a center with these combined capabilities ensures more precise long-term management.
Patient Consensus: Patients note that standard tests can miss rare variants. They recommend requesting genetic panels for genes like PKLR or SPTA1 early in the process. Many patients find that centers with advanced flow cytometry expertise provide much faster results for specific typing.
Advanced hemolytic anemia protocols in Israel integrate monoclonal antibodies and cellular therapies within JCI-accredited facilities. Specialized hematology units employ rituximab and complement inhibitors to target autoimmune destruction. Curative options include allogeneic stem cell transplantation. Automated plasma exchange provides urgent stabilization for refractory cases.
Bookimed Expert Insight: Israeli hematology leadership is defined by academic depth. Both Dr. Abraham Avigdor and Dr. Avichai Shimoni at Sheba Medical Center possess over 30+ years of experience. This expertise is a byproduct of high patient volumes. Sourasky Medical Center treats over 400,000 patients every year. These physicians don't just follow protocols. They actively author them. Dr. Avigdor has published 130+ scientific works. Dr. Shimoni has authored over 250+. For patients, this means access to research-grade diagnostics like PET/CT and experimental trials often before they reach other regions.
Patient Consensus: Patients emphasize the importance of early genetic testing to identify specific sub-types before starting steroid treatment. Many note that combining rituximab with intravenous immunoglobulin (IVIG) serves as an effective bridge therapy while waiting for long-term remission.
International patients can access clinical trials for refractory Autoimmune Hemolytic Anemia (AIHA). Eligibility depends on trial design and country-specific laws. Israeli centers often participate in global multicenter trials. Participation requires meeting strict inclusion criteria. Documented failure of standard therapies is necessary.
Bookimed Expert Insight: Israeli specialists like Dr. Hana Golan and Dr. Amos Toren serve as primary investigators for international trials. Data shows these academic headers bridge trials with compassionate use programs. If trial criteria exclude you, these experts often facilitate off-label access to newer drugs like fostamatinib.
Patient Consensus: Patients note that traveling for trials requires significant self-funding and private medical referrals. Many prioritize seeking compassionate use access to advanced therapies when formal trial residency requirements are too strict.